Shares of Fibrogen (FGEN-45.3%) are down sharply in morning trading after an FDA advisory committee voted against recommending approval of roxadustat developed by FibroGen and AstraZeneca (AZN-0.3%) ...
网页链接Shares of Fibrogen (FGEN-45.3%) are down sharply in morning trading after an FDA advisory committee voted against recommending approval of roxadustat developed by FibroGen and AstraZeneca (AZN-0.3%) ...
网页链接
精彩评论